The Binding Finding of a Fluorescence Lifetime
By Ken Tichauer
1 Ardeshirpour, Y. et al. Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm. Technology in cancer research & treatment 10, 549-560 (2011).
2 Ardeshirpour, Y. et al. In Vivo Assessment of HER2 Receptor Density in HER2-positive Tumors by Near-infrared Imaging, Using Repeated Injections of the Fluorescent Probe. Technology in cancer research & treatment, doi:10.7785/tcrtexpress.2013.600265 (2013).
3 Chernomordik, V. et al. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Molecular imaging 9, 192-200 (2010).
4 Hassan, M. et al. In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Molecular imaging 11, 177-186 (2012).
5 Zielinski, R. et al. Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PloS one 7, e41016, doi:10.1371/journal.pone.0041016 (2012).
6 Ardeshirpour, Y. et al. In-vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, (2014).
7 Ardeshirpour, Y. et al. In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PloS one 7, e31881, doi:10.1371/journal.pone.0031881 (2012).
8 Innis, R. B. et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533-1539, doi:10.1038/sj.jcbfm.9600493 (2007).
9 Tichauer, K. M. et al. Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. Journal of Biomedical Optics 17, (2012).
Posted: 27 April 2014 by Ken Tichauer | with 0 comments
The views expressed by guest contributors to the Discover OSA Blog are not those endorsed by The Optical Society.